J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.